Similar and Promising Outcomes in Lymphoma Patients Treated with Myeloablative or Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 5, 2008, Pages 538-545

  Tomblyn, Marcie ^a   Brunstein, Claudio ^a   Burns, Linda J ^a   Miller, Jeffrey S ^a   MacMillan, Margaret ^a   DeFor, Todd E ^a   Weisdorf, Daniel J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Lymphoma Allogeneic transplantation Nonmyeloablative

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BACTERIAL INFECTION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; RADIATION DOSE FRACTIONATION; RECIPIENT; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; RISK REDUCTION; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; VIRUS INFECTION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 41849145733     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.02.014     Document Type: Article

References (25)

1. SEER Program (National Cancer Institute [U.S.]), National Institutes of Health (U.S.), National Cancer Institute (U.S.). Surveillance Program. SEER Cancer Statistics Review.
2. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
3. CIBMTR Summary Slides. http://www.cibmtr.org/SERVICES/Observational_Research/Summary_Slides/index.html.
4. Verdonck L.F., Dekker A.W., Lokhorst H.M., Petersen E.J., and Nieuwenhuis H.K. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 90 (1997) 4201-4205
5. van Besien K., Loberiza Jr. F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102 (2003) 3521-3529
6. van Besien K., Sobocinski K.A., Rowlings P.A., et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92 (1998) 1832-1836
7. Peggs K.S., Hunter A., Chopra R., et al. Clinical evidence of a graft-versus-Hodgkin's lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365 (2005) 1934-1941
8. Bertz H., Illerhaus G., Veelken H., and Finke J. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 13 (2002) 135-139
9. Rodriguez R., Nademanee A., Ruel N., et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 12 (2006/12) 1326-1334
10. Sorror M.L., Storer B.E., Maloney D.G., Sandmaier B.M., Martin P.J., and Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111 (2008) 446-452
11. Sureda A., Robinson S., Canals C., et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26 (2008) 455-462
12. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
13. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. Blood 110 (2007) 3064-3070
14. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825-828
15. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 16 (1997) 901
16. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457
17. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244
18. Cox D.R. Regression models and life tables. J R Stat Soc B 34 (1972) 187
19. Fine J.P., and Gray R.J. A proportional hazard model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999) 496
20. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
21. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (2002) 4310-4316
22. Corradini P., Dodero A., Farina L., et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 21 (2007) 2316-2323
23. Vigouroux S., Michallet M., Porcher R., et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 92 (2007) 627-634
24. Khouri I.F., Saliba R.M., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98 (2001) 3595-3599
25. Khouri I.F., Lee M., Saliba R.M., et al. Non-myeloablative allogeneic transplantation (NMT) with T-cell replete graft for relapsed chemosensitive follicular lymphoma (FL): Donor lymphocyte infusion (DLI) to convert stable mixed chimerism to full donor chimerism is not necessary in the absence of disease progression. Blood 106 (2005) 3659